A trio of biotech entrepreneurs and investors launched a new biotech-focused VC firm called Curie.bio.
The firm secured $520M from investors such as GV, Andreessen Horowitz, and ARCH Venture Partners for its debut fund. In addition to leading investments, the firm aspires to serve as a "co-pilot" for drug discovery startups.
- Zach Weinberg established the firm along with former Third Rock Ventures partners Alexis Borisy and Christoph Lengauer.
- Weinberg, founder of Flatiron Health, which was acquired by Roche in 2018, will lead the firm as its CEO.
- Borisy and Lengauer will step into chairman and chief scientific officer roles, respectively.
- Curie.bio's individual check sizes in seed-stage startups will range between $5M and $7M.
- The firm has already backed four companies, namely Forward Therapeutics, Astoria Biologica, Decrypt Biomedicine, and Differentiated Therapeutics.